Skip to content
Screener

Regeneron Pharmaceuticals REGN Gross Profit

Discontinued — last reported Q4 '19

Gross Profit at other companies

Merck & Co. logo
Merck & Co.MRK
$12.09B-0.2%
Amgen logo
AmgenAMGN
$5.87B+13.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$21.81M+2.9%
Glaukos logo
GlaukosGKOS
$151.59M+55.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$9.46M+0.2%

Other financials

Income statement

See full
Revenue$4.3B+16.7%
Operating income$1.3B+19.8%
Net income$1.3B-6.8%
EPS (diluted)$12.23-4.5%

Balance sheet

See full
Cash & equivalents$2.5B+22.3%
Total debt$2.7B+0.1%
Total equity$31.7B+5.9%
Total assets$41.7B+9.2%

Cash flow

See full
Operating cash flow$813.0M-29.0%
CapEx$240.2M+9.7%
Free cash flow$572.8M-38.1%

Valuation

See full
Market cap$78.52B+29.6%
Enterprise value$78.76B+28.6%
P/E18.1×+4.6×
P/S5.1×+0.8×

Profitability

See full
Gross margin94.9%—
Operating margin24.7%-2.3pp
Net margin27.9%-3.5pp
FCF margin24.2%-2.9pp

Returns & leverage

See full
Return on equity14%-1.3pp
Debt / equity0.1×0.0×
Current ratio3.3×-1.3×

Where this comes from

Calculated from Regeneron Pharmaceuticals’s reported figures.

$2.2Btotal revenue−$100.7Mtotal cost of revenue=$1.87B

The source filing: Regeneron Pharmaceuticals’s 10-K, filed February 8, 2021. Open the filing →

Filed
Feb 7, 2021, 7:00 PM EST
Fiscal year
FY2020
Accession
0001804220-21-000008

FAQ

What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.